The present invention provides methods for producing and/or expanding tumor-infiltrating lymphocytes (TILs) that can be used in adoptive immunotherapy in cancer treatment.

A borophosphate glass composition including B.sub.2O.sub.3, P.sub.2O.sub.5, and CaO, and optionally a source additive selected from: Li.sub.2O, Na.sub.2O, K.sub.2O, Al.sub.2O.sub.3, ZnO, MgO, Fe.sub.2O.sub.3/FeO, CuO/Cu.sub.2O, and mixtures thereof, as defined herein. Also disclosed are bioactive compositions or substrates including the disclosed borophosphate glass composition, and at least one live cell. Also disclosed are methods of inhibiting or increasing the relative amount of species containing boron, phosphorous, or both, being released into an aqueous solution from aborophosphate glass composition defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein. Also disclosed are related glass compositions that exclude one of B.sub.2O.sub.3, P.sub.2O.sub.5, and CaO.

The invention relates to a method for obtaining endothelial cells from human pluripotent stem cells.

Disclosed herein are methods and compositions for treating or preventing ovarian failure using fibroblasts or cells derived from fibroblasts. In some embodiments, ovarian failure is pathological, the result of an intervention, or the result of aging. In some embodiments, regenerative fibroblast cells are administered locally into the ovary or pen-ovary areas or systemically. In some embodiments, regenerative cells act to suppress fibrosis of the ovaries, inhibit inflammation, stimulate maturation of immature ovarian progenitor cells, or directly differentiate into oocytes. In some embodiments, regenerative fibroblasts produce factors that inhibit apoptosis of oocytes and/or oocyte progenitors.

There is described herein a method of enriching a population of stem cells for hematopoietic progenitors. The method comprises inducing hematopoietic differentiation in a population of human embryonic stem cells or human induced pluripotent stem cells; sorting the population based on expression of CD43 and at least one of CD34, CD31 and CD144; and selecting a fraction that is at least one of CD34+CD43−, CD31+CD43− and CD144+CD43−. Also provided are populations of hematopoietic progenitors obtained by the methods described herein.

Methods for generating human arterial endothelial cells under defined conditions in the absence of insulin are described. In particular, provided herein are efficient, defined, and scalable methods for generating human arterial endothelial cells from human pluripotent stem cells. Also provided herein are uses of human arterial endothelial cells obtained according to these methods. For example, methods of treating peripheral arterial disease and methods of screening agents for that effect adhesion of leukocytes to arterial endothelial cells are also provided.

An aluminoborate glass composition, including B.sub.2O.sub.3, Al.sub.2O.sub.3, P.sub.2O.sub.5, Na.sub.2O, and CaO, as defined herein. Also disclosed are bioactive compositions including the disclosed aluminoborate glass composition, a suitable fluid, and at least one live cell. Also disclosed is method of limiting the amount of boron released into an aqueous solution from a disclosed aluminoborate-containing glass composition as defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein.

The present disclosure relates generally to methods and compositions useful in cell and tissue biology and therapeutics. In particular, an in vitro method for differentiating pluripotent stem cells into KDR.sup.+NCAM.sup.+APLNR.sup.+ mesoderm cells and/or SSEA5.sup.−KDR.sup.+NCAM.sup.+APLNR.sup.+ mesoderm cells is provided. The disclosed mesoderm cells may be used to generate blood vessels in vivo and/or further differentiated in vitro into endothelial colony forming cell-like cells (ECFC-like cells). Purified human cell populations of KDR.sup.+NCAM.sup.+APLNR.sup.+ mesoderm cells and ECFC-like cells are provided. Test agent screening and therapeutic methods for using the cell populations of the present disclosure are provided.

The present invention relates to endothelial cells and methods of generating endothelial cells from pluripotent stem cells.

The present invention provides a method for producing or detecting cardiomyocytes by extracting/detecting cardiomyocytes from a cell population which includes cardiomyocytes using, as an index, positivity of NCAM1, SSEA3, SSEA4 and/or CD340.